At the beginning of the year, CombiMatrix provided preliminary annual growth figures which excited investors, sending the shares soaring as high as $6.64. Prenatal tests grew by a stunning 172 percent year over year. In addition, overall billable tests volumes grew 25%. Despite this extraordinary growth, shares have since slowly retreated by more than 1/2 as the fast money has moved on and the news flow has been quiet. This brings us to the catalyst on the immediate horizon that will in all probability launch shares higher. CombiMatrix is scheduled to report results and hold an investor call in late February. I believe the Street has long forgotten this impressive guidance and that investors and traders are not positioned for this event. As a result, I expect shares are poised for a breathtaking rally as this news flow hits the tape.